8-K Announcements
6Material company update
Apr 15, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Feb 17, 2026·SEC
GeoVax Labs, Inc.(GOVX)Earnings, Financials & Key Ratios
GOVX•NASDAQ
$1.65
$2M mkt cap·Price updated May 6, 2026
AboutGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.Show more
- Revenue$2M-37.1%
- EBITDA-$22M+13.6%
- Net Income-$21M+14.1%
- EPS (Diluted)-22.40+81.4%
- Gross Margin100%+2.5%
- EBITDA Margin-869.34%-37.2%
- Operating Margin-869.34%-36.7%
- Net Margin-862.34%-36.4%
- ROE-0%+100.0%
- ROIC-0%
- Debt/Equity0.22
GOVX Key Insights
GeoVax Labs, Inc. (GOVX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Profits declining 48.6% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GOVX Price & Volume
GeoVax Labs, Inc. (GOVX) stock price & volume — 10-year historical chart
Loading chart...
GOVX Growth Metrics
GeoVax Labs, Inc. (GOVX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years19.25%
5 Years6.42%
3 Years212.55%
TTM-37.06%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.11%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM79.73%
Return on Capital
10 Years-210.54%
5 Years-190.13%
3 Years-210.13%
Last Year-0%
GOVX Peer Comparison
GeoVax Labs, Inc. (GOVX) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% | |||
 IOVA | 1.68B | 4.09 | -3.75 | 60.6% | -148.38% | -55.97% | 0.07 | |
 DVAX | 1.82B | 15.50 | 77.50 | 19.36% | -13.13% | -8.13% | 0.43 | |
 SIGA | 336.57M | 4.70 | 14.24 | -31.8% | 24.64% | 0% | 0 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 INO | 581.39M | 1.24 | -0.69 | -100% | -14.06% | 0.39 | ||
 VXRT | 179.17M | 0.75 | 10.64 | 7.27% | 6.88% | 33.83% | 0.10 |
Compare GOVX vs Peers
GeoVax Labs, Inc. (GOVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GOVX Income Statement
GeoVax Labs, Inc. (GOVX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.08M | 963K | 1.18M | 1.82M | 385.5K | 81.53K | 0 | 3.95M | 2.49M |
| Revenue Growth % | 29.72% | -10.44% | 22.11% | 55.09% | -78.86% | -78.85% | -100% | - | -37.06% |
| Cost of Goods Sold | 2.02M | 1.88M | 0 | 0 | 0 | 9.12M | 20.72M | 95.37K | 0 |
| COGS % of Revenue | 187.61% | 195.08% | - | - | - | 11190.88% | - | 2.41% | - |
| Gross Profit | -942.08K▲ 0% | -915.65K▲ 2.8% | 1.18M▲ 228.4% | 1.82M▲ 55.1% | 385.5K▼ 78.9% | -9.04M▼ 2445.5% | -20.72M▼ 129.2% | 3.86M▲ 118.6% | 2.49M▼ 35.5% |
| Gross Margin % | -87.61% | -95.08% | 100% | 100% | 100% | -11090.88% | - | 97.59% | 100% |
| Gross Profit Growth % | 17.5% | 2.81% | 228.42% | 55.09% | -78.86% | -2445.51% | -129.16% | 118.62% | -35.5% |
| Operating Expenses | 3.25M | 3.53M | 3.55M | 4.64M | 19.13M | 4.99M | 6.02M | 29M | 24.13M |
| OpEx % of Revenue | 302.22% | 366.15% | 301.76% | 254.46% | 4962.72% | 6116.59% | - | 733.42% | 969.34% |
| Selling, General & Admin | 1.23M | 1.65M | 1.64M | 2.2M | 3.58M | 4.99M | 5.95M | 5.39M | 6.01M |
| SG&A % of Revenue | 114.61% | 171.03% | 139.27% | 120.42% | 927.92% | 6116.59% | - | 136.18% | 241.31% |
| Research & Development | 2.02M | 1.88M | 1.91M | 2.44M | 15.55M | 9.12M | 20.72M | 23.71M | 18.12M |
| R&D % of Revenue | 187.61% | 195.12% | 162.49% | 134.04% | 4034.79% | 11190.88% | - | 599.65% | 728.02% |
| Other Operating Expenses | 0 | 3K | 0 | 0 | 0 | -9.12M | -20.65M | -95.37K | 0 |
| Operating Income | -2.17M▲ 0% | -2.56M▼ 17.9% | -2.37M▲ 7.4% | -2.82M▼ 18.7% | -18.75M▼ 565.5% | -14.03M▲ 25.2% | -26.74M▼ 90.6% | -25.14M▲ 6.0% | -21.64M▲ 13.9% |
| Operating Margin % | -202.22% | -266.15% | -201.76% | -154.46% | -4862.72% | -17207.47% | - | -635.83% | -869.34% |
| Operating Income Growth % | 33.57% | -17.87% | 7.43% | -18.73% | -565.5% | 25.16% | -90.63% | 5.98% | 13.94% |
| EBITDA | -2.15M | -2.54M | -2.36M | -2.8M | -18.71M | -13.97M | -26.67M | -25.05M | -21.64M |
| EBITDA Margin % | -199.62% | -264.09% | -201.05% | -153.38% | -4852.72% | -17138.43% | - | -633.42% | -869.34% |
| EBITDA Growth % | 33.85% | -18.49% | 7.04% | -18.32% | -568.8% | 25.31% | -90.87% | 6.07% | 13.61% |
| D&A (Non-Cash Add-back) | 28.03K | 19.8K | 8.35K | 19.66K | 38.52K | 56.28K | 74.17K | 95.37K | 0 |
| EBIT | -2.17M | -2.56M | -2.37M | -2.81M | -18.57M | -14.03M | -26.74M | -24.97M | -21.64M |
| Net Interest Income | 4.29K | 2.62K | 1.86K | -141.25K | 3.45K | 7.44K | 776.18K | 151.98K | 174.28K |
| Interest Income | 4.29K | 5.21K | 6.36K | 2.27K | 4.74K | 7.44K | 776.18K | 173.36K | 174.28K |
| Interest Expense | 0 | 2.59K | 4.5K | 143.52K | 1.29K | 0 | 0 | 21.38K | 0 |
| Other Income/Expense | 4.29K | 2.62K | 1.86K | -141.25K | 175.51K | 7.44K | 776.18K | 151.98K | 174.28K |
| Pretax Income | -2.17M▲ 0% | -2.56M▼ 18.0% | -2.37M▲ 7.4% | -2.96M▼ 24.8% | -18.57M▼ 527.8% | -14.02M▲ 24.5% | -25.97M▼ 85.2% | -24.99M▲ 3.8% | -21.46M▲ 14.1% |
| Pretax Margin % | -201.82% | -265.84% | -201.6% | -162.21% | -4817.19% | -17198.35% | - | -631.98% | -862.34% |
| Income Tax | 0 | 5.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | -0.2% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -2.17M▲ 0% | -2.56M▼ 18.0% | -2.37M▲ 7.4% | -2.96M▼ 24.8% | -18.57M▼ 527.8% | -14.02M▲ 24.5% | -25.97M▼ 85.2% | -24.99M▲ 3.8% | -21.46M▲ 14.1% |
| Net Margin % | -201.82% | -265.84% | -201.6% | -162.21% | -4817.19% | -17198.35% | - | -631.98% | -862.34% |
| Net Income Growth % | 33.67% | -17.96% | 7.4% | -24.78% | -527.79% | 24.5% | -85.2% | 3.75% | 14.11% |
| Net Income (Continuing) | -2.17M | -2.56M | -2.37M | -2.96M | -18.57M | -14.02M | -25.97M | -24.99M | -21.46M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -21.25▲ 0% | -25.25▼ 18.8% | -23.50▲ 6.9% | -29.00▼ 23.4% | -182.50▼ 529.3% | -138.00▲ 24.4% | -255.50▼ 85.1% | -120.50▲ 52.8% | -22.40▲ 81.4% |
| EPS Growth % | 34.11% | -18.82% | 6.93% | -23.4% | -529.31% | 24.38% | -85.14% | 52.84% | 81.41% |
| EPS (Basic) | -21.25 | -25.25 | -23.50 | -29.00 | -182.50 | -138.00 | -255.50 | -120.50 | -22.40 |
| Diluted Shares Outstanding | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 207.48K | 958.44K |
| Basic Shares Outstanding | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 101.59K | 207.48K | 958.44K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
GOVX Balance Sheet
GeoVax Labs, Inc. (GOVX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 448.07K | 620K | 447.26K | 10.23M | 11.63M | 28.94M | 7.89M | 7.93M | 5.31T |
| Cash & Short-Term Investments | 312.73K | 260K | 283.34K | 9.88M | 11.42M | 27.61M | 6.45M | 5.51M | 5.51M |
| Cash Only | 312.73K | 260K | 283.34K | 9.88M | 11.42M | 27.61M | 6.45M | 5.51M | 5.51M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 59.76K | 121.81K | 68.6K | 182.66K | 49.01K | 0 | 0 | 659.41K | 0 |
| Days Sales Outstanding | 20.28 | 46.17 | 21.29 | 36.56 | 46.4 | - | - | 60.86 | - |
| Inventory | 0 | -121.81K | 0 | 0 | -49.01K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | -352 | 48.76K | 0 | 0 | 0 | 2.23T |
| Total Non-Current Assets | 42.16K | 22K | 21.62K | 159K | 168K | 2.41M | 1.4M | 220.98K | 1.03T |
| Property, Plant & Equipment | 31.15K | 22K | 10.61K | 159K | 168K | 2.41M | 209.69K | 149.97K | 940.27B |
| Fixed Asset Turnover | 34.52x | 43.77x | 110.87x | 11.47x | 2.29x | 0.03x | - | 26.37x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 80K | 70K | 60K | 50K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 11.01K | 0 | 11.01K | 0 | 0 | -80K | 1.12M | 11.01K | 86.95B |
| Total Assets | 490.24K▲ 0% | 642K▲ 31.0% | 468.88K▼ 27.0% | 10.39M▲ 2116.8% | 11.8M▲ 13.5% | 31.35M▲ 165.7% | 9.28M▼ 70.4% | 8.16M▼ 12.1% | 6.34T▲ 77758254.8% |
| Asset Turnover | 2.19x | 1.50x | 2.51x | 0.18x | 0.03x | 0.00x | - | 0.48x | 0.00x |
| Asset Growth % | -19.66% | 30.96% | -26.97% | 2116.77% | 13.5% | 165.73% | -70.39% | -12.14% | 77758254.81% |
| Total Current Liabilities | 811.29K | 1.62M | 2.02M | 810.31K | 5.44M | 4.75M | 3.52M | 3.11M | 1.94T |
| Accounts Payable | 77.58K | 125.86K | 152.65K | 267.7K | 2.06M | 1.75M | 2.8M | 1.85M | 790.75K |
| Days Payables Outstanding | 14.04 | 24.45 | - | - | - | 69.92 | 49.37 | 7.08K | - |
| Short-Term Debt | 0 | 260.42K | 12.5K | 183.33K | 0 | 0 | 0 | 0 | 263.13B |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 270.88K | 1.67T |
| Current Ratio | 0.55x | 0.38x | 0.22x | 12.63x | 2.14x | 6.10x | 2.24x | 2.55x | 2.74x |
| Quick Ratio | 0.55x | 0.46x | 0.22x | 12.63x | 2.15x | 6.10x | 2.24x | 2.55x | 2.74x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 39.58K | 27.24K | 14.74K | 2M | 0 | 0 | 0 | 580.03B |
| Long-Term Debt | 0 | 39.58K | 27.24K | 14.74K | 0 | 0 | 0 | 0 | 580.03B |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 2M | 0 | 0 | 0 | 0 |
| Total Liabilities | 811.29K | 1.66M | 2.04M | 825K | 7.43M | 4.75M | 3.52M | 3.11M | 2.52T |
| Total Debt | 0 | 300K | 39.74K | 198.06K | 0 | 0 | 0 | 0 | 843.17B |
| Net Debt | -312.73K | 40K | -243.6K | -9.69M | -11.42M | -27.61M | -6.45M | -5.51M | 843.16B |
| Debt / Equity | - | - | - | 0.02x | - | - | - | - | 0.22x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -987.45x | -526.39x | -19.61x | -14439.37x | - | - | -1168.23x | - |
| Total Equity | -321.06K▲ 0% | -1.02M▼ 218.3% | -1.57M▼ 54.1% | 9.57M▲ 707.7% | 4.36M▼ 54.4% | 26.6M▲ 509.8% | 5.76M▼ 78.3% | 5.05M▼ 12.4% | 3.83T▲ 75767068.1% |
| Equity Growth % | -233.57% | -218.32% | -54.07% | 707.73% | -54.42% | 509.81% | -78.33% | -12.4% | 75767068.1% |
| Book Value per Share | -3.16 | -10.06 | -15.50 | 94.19 | 42.94 | 261.82 | 56.73 | 24.33 | 999999.00 |
| Total Shareholders' Equity | -321.06K | -1.02M | -1.57M | 9.57M | 4.36M | 26.6M | 5.76M | 5.05M | 3.83T |
| Common Stock | 106.74K | 218.9K | 300 | 3.83K | 6.38K | 26.34K | 1.98K | 10.54K | 1.73K |
| Retained Earnings | -37.92M | -40.48M | -42.85M | -45.81M | -64.38M | -78.4M | -104.36M | -129.36M | -150.82T |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -663.25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GOVX Cash Flow Statement
GeoVax Labs, Inc. (GOVX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.69M | -1.54M | -1.4M | -2.75M | -11.2M | -19.03M | -25.17M | -24.68M | -21.47M |
| Operating CF Margin % | -157.03% | -160.23% | -118.93% | -150.83% | -2904.38% | -23342.5% | - | -623.97% | -862.7% |
| Operating CF Growth % | 13.24% | 8.61% | 9.37% | -96.68% | -307.06% | -69.97% | -32.28% | 1.98% | 12.97% |
| Net Income | -2.17M | -2.56M | -2.37M | -2.96M | -18.57M | -14.02M | -25.97M | -24.99M | -21.46M |
| Depreciation & Amortization | 28.03K | 19.8K | 8.35K | 19.66K | 38.52K | 56.28K | 74.17K | 95.37K | 68.76K |
| Stock-Based Compensation | 57.22K | 469.72K | 327.5K | 64.46K | 369.99K | 902.07K | 1.07M | 528.64K | 1.12M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -3.65M | 0 | 0 | 0 |
| Other Non-Cash Items | -296.48K | 18.26K | 0 | 124.19K | 37.77K | 3.65M | 0 | 0 | 0 |
| Working Capital Changes | 396.45K | 527.54K | 636.28K | -806 | 6.93M | -5.97M | -356K | -307.23K | -1.19M |
| Change in Receivables | -31.68K | -62.06K | 53.21K | -114.06K | 133.66K | 49.01K | 0 | -659.41K | 659.41K |
| Change in Inventory | 0 | 0 | 0 | 114.06K | -133.66K | -49.01K | 0 | 0 | 0 |
| Change in Payables | 441.44K | 553.12M | 639.28K | 137.96B | 6.81T | -2.69M | -1.23M | -412.55K | 0 |
| Cash from Investing | -4.35K | 0 | -7.61K | -156.79K | -47.72K | -134.26K | -48.95K | -20.65K | -27.61K |
| Capital Expenditures | -4.35K | 0 | -7.61K | -156.79K | -47.72K | -134.26K | -48.95K | -20.65K | -27.61K |
| CapEx % of Revenue | 0.4% | - | 0.65% | 8.6% | 12.38% | 164.68% | - | 0.52% | 1.11% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.55M | 1.49M | 1.43M | 12.51M | 12.78M | 35.35M | 4.06M | 23.75M | 19.08M |
| Debt Issued (Net) | 0 | 300K | -10.26K | 1.05M | -27.86K | 0 | 0 | -15K | 0 |
| Equity Issued (Net) | 0 | 1.19M | 1.44M | 11.46M | 9.41M | 27.73M | 4.06M | 21.4M | 19.08M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -1K | 0 | 0 | 0 | 0 |
| Other Financing | 1.55M | 0 | 0 | 2.5K | 3.4M | 7.63M | 0 | 2.37M | 0 |
| Net Change in Cash | -141.3K▲ 0% | -53.03K▲ 62.5% | 23.64K▲ 144.6% | 9.6M▲ 40511.1% | 1.54M▼ 84.0% | 16.19M▲ 951.2% | -21.16M▼ 230.7% | -945.65K▲ 95.5% | -2.42M▼ 156.0% |
| Free Cash Flow | -1.69M▲ 0% | -1.54M▲ 8.8% | -1.41M▲ 8.9% | -2.91M▼ 106.8% | -11.24M▼ 286.7% | -19.16M▼ 70.4% | -25.22M▼ 31.6% | -24.7M▲ 2.1% | -21.5M▲ 12.9% |
| FCF Margin % | -157.43% | -160.23% | -119.58% | -159.42% | -2916.76% | -23507.18% | - | -624.5% | -863.81% |
| FCF Growth % | 90.49% | 8.85% | 8.87% | -106.77% | -286.75% | -70.44% | -31.61% | 2.09% | 12.94% |
| FCF per Share | -16.66 | -15.19 | -13.84 | -28.62 | -110.68 | -188.64 | -248.27 | -119.03 | -22.43 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.60x | 0.59x | 0.93x | 0.60x | 1.36x | 0.97x | 0.99x | 1.00x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GOVX Key Ratios
GeoVax Labs, Inc. (GOVX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -452.84% | - | - | - | -74% | -266.6% | -90.57% | -160.47% | -462.31% | -0% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | -0% |
| Gross Margin | -137.76% | -87.61% | -95.08% | 100% | 100% | 100% | -11090.88% | - | 97.59% | 100% |
| Net Margin | -394.7% | -201.82% | -265.84% | -201.6% | -162.21% | -4817.19% | -17198.35% | - | -631.98% | -862.34% |
| Debt / Equity | - | - | - | - | 0.02x | - | - | - | - | 0.22x |
| Interest Coverage | - | - | -987.45x | -526.39x | -19.61x | -14439.37x | - | - | -1168.23x | - |
| FCF Conversion | 0.59x | 0.78x | 0.60x | 0.59x | 0.93x | 0.60x | 1.36x | 0.97x | 0.99x | 1.00x |
| Revenue Growth | 93.64% | 29.72% | -10.44% | 22.11% | 55.09% | -78.86% | -78.85% | -100% | - | -37.06% |
GOVX SEC Filings & Documents
GeoVax Labs, Inc. (GOVX) SEC filings — annual & quarterly reports (10-K, 10-Q)
GOVX Frequently Asked Questions
GeoVax Labs, Inc. (GOVX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
GeoVax Labs, Inc. (GOVX) reported $2.5M in revenue for fiscal year 2025. This represents a 2550% increase from $0.1M in 1996.
GeoVax Labs, Inc. (GOVX) saw revenue decline by 37.1% over the past year.
GeoVax Labs, Inc. (GOVX) reported a net loss of $21.5M for fiscal year 2025.
Dividend & Returns
GeoVax Labs, Inc. (GOVX) has a return on equity (ROE) of -0.0%. Negative ROE indicates the company is unprofitable.
GeoVax Labs, Inc. (GOVX) had negative free cash flow of $21.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More GOVX
GeoVax Labs, Inc. (GOVX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates